We are live on
!
Find out more
TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Est. Return
18.15%
This Fund
S&P 500
This Quarter
Est. Return
-0.34%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.63B
AUM Growth
-$21.2M
(-0.8%)
Cap. Flow
+$40.7M
Cap. Flow
% of AUM
1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.68%
Holding
190
New
18
Increased
27
Reduced
27
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$47.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$18.8M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$18M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$16.7M |
| 5 |
Pfizer
PFE
|
+$13.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$47.2M |
| 2 |
Stryker
SYK
|
+$24.6M |
| 3 |
Zimmer Biomet
ZBH
|
+$24M |
| 4 |
Humana
HUM
|
+$20.2M |
| 5 |
UnitedHealth
UNH
|
+$17.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.54% |
| 2 | Real Estate | 2.01% |
| 3 | Industrials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Amgen
AMGN
$209B
| $134M | 5.12% |
555,939
+47,263
| +9% | +$11.6M |
|
2
Gilead Sciences
GILD
$163B
| $129M | 4.93% |
1,559,884
+49,444
| +3% | +$4.1M |
|
|
3
Regeneron Pharmaceuticals
REGN
$77.4B
| $118M | 4.48% |
143,053
+22,191
| +18% | +$16.7M |
|
4
Johnson & Johnson
JNJ
$617B
| $112M | 4.26% |
721,779
+82,100
| +13% | +$13.3M |
|
|
5
UnitedHealth
UNH
$383B
| $111M | 4.21% |
234,173
-36,373
| -13% | -$17.6M |
|
6
Vertex Pharmaceuticals
VRTX
$122B
| $104M | 3.96% |
330,343
| – | – |
|
7
Eli Lilly
LLY
$1.03T
| $99.2M | 3.78% |
288,917
| – | – |
|
8
AbbVie
ABBV
$455B
| $81.5M | 3.1% |
511,599
+33,257
| +7% | +$5.08M |
|
9
Illumina
ILMN
$31B
| $80.9M | 3.08% |
357,825
+28,908
| +9% | +$5.92M |
|
|
10
Pfizer
PFE
$142B
| $72.4M | 2.76% |
1,775,076
+317,906
| +22% | +$13.7M |
|
11
AstraZeneca
AZN
$266B
| $68.9M | 2.62% |
496,332
-14,796
| -3% | -$1.99M |
|
12
Biogen
BIIB
$30.7B
| $67M | 2.55% |
240,926
+45,496
| +23% | +$12.6M |
|
13
Abbott
ABT
$183B
| $63.2M | 2.41% |
623,855
-69,196
| -10% | -$7.31M |
|
14
Merck
MRK
$321B
| $58.7M | 2.24% |
552,122
| – | – |
|
15
Thermo Fisher Scientific
TMO
$214B
| $54M | 2.06% |
93,705
| – | – |
|
|
16
Elevance Health
ELV
$81.6B
| $52.5M | 2% |
114,070
+99,426
| +679% | +$47.3M |
|
17
Moderna
MRNA
$23B
| $49.5M | 1.88% |
322,217
+57,290
| +22% | +$9.45M |
|
18
Cigna
CI
$76.1B
| $46.7M | 1.78% |
182,631
| – | – |
|
19
Bristol-Myers Squibb
BMY
$132B
| $46M | 1.75% |
663,796
-23,733
| -3% | -$1.67M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $45.5M | 1.73% |
224,663
+112,449
| +100% | +$18M |
|
|
21
Sarepta Therapeutics
SRPT
$1.64B
| $39.4M | 1.5% |
285,653
+144,694
| +103% | +$18.8M |
|
22
argenx
ARGX
$54.6B
| $32.9M | 1.25% |
88,310
+4,289
| +5% | +$1.59M |
|
23
Idexx Laboratories
IDXX
$44.1B
| $29.3M | 1.12% |
58,595
-9,470
| -14% | -$4.53M |
|
24
BioMarin Pharmaceuticals
BMRN
$11.7B
| $29.2M | 1.11% |
300,089
+69,299
| +30% | +$7.18M |
|
25
Intuitive Surgical
ISRG
$126B
| $28.8M | 1.1% |
112,680
| – | – |
|
Similar funds
EST
VIA
AWS
JP
VCM
FCFS
FCB
BWM
Tekla Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Tekla Capital Management held 190 positions worth $2.63B, down 0.8% from $2.65B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Tekla Capital Management's Q1 2023 filing shows 18 new, 27 increased, 27 reduced and 13 closed positions. Its largest new stake was Exelixis: 726,639 shares worth $14.1M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $47.2M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Real Estate and Industrials.
- Tekla Capital Management's largest Q1 2023 buy was Exelixis: 726,639 shares worth $14.1M.
- Tekla Capital Management added most to Elevance Health in Q1 2023, an estimated $47.3M increase.
- Tekla Capital Management's biggest Q1 2023 reduction was Stryker, cutting an estimated $24.6M.
- Tekla Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, selling an estimated $47.2M.
- Tekla Capital Management's ten largest holdings make up 40% of its $2.63B portfolio in Q1 2023.
- Tekla Capital Management opened 18 new positions and closed 13 in Q1 2023.
- Tekla Capital Management's portfolio value fell 0.8% quarter-over-quarter to $2.63B.
Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.